cis-2-aza-3-oxobicyclo<3.2.0>heptane | 22031-52-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: cis-2-aza-3-oxobicyclo<3.2.0>heptane
• 英文别名: (±)-cis-6-azabicyclo[3.2.0]heptan-7-one；(+/-)-6-azabicyclo[3.2.0]heptan-7-one；2-amino-cyclopentanecarboxylic acid；cis-6-azabicyclo[3.2.0]heptan-7-one；6-azabicyclo[3.2.0]heptan-7-one；MNR7；(1R,5S)-6-azabicyclo[3.2.0]heptan-7-one
• CAS: 22031-52-3；39155-94-7；39155-95-8；83151-31-9
• 化学式: C₆H₉NO
• 分子量: 111.144
• InChiKey: AXDBIGNYXNSBHV-UHNVWZDZSA-N

物化性质

• 熔点：
  45-50 °C
• 沸点：
  208.27°C (rough estimate)
• 密度：
  1.0656 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi-F,F,Xi
• 安全说明：
  S16,S26,S37/39
• 危险类别码：
  R36/37/38,R11
• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存放于阴凉干燥处。

SDS

Name:	6-Azabicyclo[3.2.0]Heptan-7-one 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	22031-52-3

Section 1 - Chemical Product MSDS Name:6-Azabicyclo[3.2.0]Heptan-7-one 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
22031-52-3	6-Azabicyclo[3.2.0]Heptan-7-one	98%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Light sensitive.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam. Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Store protected from light.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store protected from light.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 22031-52-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 41-42 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H9NO
Molecular Weight: 111.0691

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, light, dust generation.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 22031-52-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-Azabicyclo[3.2.0]Heptan-7-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 22031-52-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 22031-52-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 22031-52-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  cis-2-aza-3-oxobicyclo<3.2.0>heptane 在 水 作用下， 以 异丙醚 为溶剂， 反应 240.0h， 以21%的产率得到(1R,2S)-2-氨基-1-环戊烷羧酸
  参考文献：
  名称：

  Hairpin Folding Behavior of Mixed α/β-Peptides in Aqueous Solution

  摘要：

  The invention of new strategies for the design of protein-mimetic oligomers that manifest the folding encoded in natural amino acid sequences is a significant challenge. In contrast to the a-helix, mimicry of protein beta-sheets is less understood. We report here the aqueous folding behavior of a prototype alpha-peptide hairpin model sequence varied at cross-strand positions by incorporation of 16 different beta-amino acid monomers. Our results provide a folding propensity scale for beta-residues in a protein beta-sheet context as well as high-resolution structures of several mixed-backbone alpha/beta-peptide hairpins in water.

  DOI：

  10.1021/ja2002346
• 作为产物：
  描述：

  (1S,5R)-7-oxo-6-azabicyclo[3.2.0]heptane-6-sulfonyl chloride 在 sodium sulfite 作用下， 生成 cis-2-aza-3-oxobicyclo<3.2.0>heptane
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel bicyclic β-lactams as potential antimalarials

  摘要：

  A series of bicyclic N-substituted and unsubstituted beta-lactams were synthesized and evaluated as targeted potential antimalarials. The compounds MNR4 and MNR5 were found to have highest potency against Plasmodium falciparum in vitro. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.011

文献信息

• 2,4-diamino-pyrimidines as aurora inhibitors
  申请人：Zahn Karl Stephan

  公开号：US20070032514A1

  公开（公告）日：2007-02-08

  The present invention encompasses compounds of general formula (1) wherein R 1 to R 3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物 其中 R 1 至 R 3 如权利要求书中所定义，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物组合物。
• Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
  申请人：Levin I. Jeremy

  公开号：US20060211730A1

  公开（公告）日：2006-09-21

  This invention provides compounds of Formula I, having the structure: that are useful in treating diseases or disorders mediated by TNF-α, such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compounds.

  这项发明提供了具有结构的Formula I的化合物，这些化合物在治疗由TNF-α介导的疾病或紊乱方面非常有用，如关节炎（类风湿关节炎（RA），幼年RA，银屑病性关节炎，骨关节炎等），肿瘤转移，组织溃疡，异常伤口愈合，牙周病，骨病，糖尿病（胰岛素抵抗）和HIV感染，强直性脊柱炎，银屑病，败血症，多发性硬化，克罗恩病，退行性软骨丢失，哮喘，特发性肺纤维化，血管炎，系统性红斑狼疮，肠易激综合征，急性冠状动脉综合征，丙型肝炎，虚弱，慢性阻塞性肺病，中风或2型糖尿病的缓解症状。该发明还提供了使用这些化合物的方法。
• New compounds
  申请人：Zahn Stephan Karl

  公开号：US20090163467A1

  公开（公告）日：2009-06-25

  The present invention encompasses compounds of general formula (1) wherein R 1 , R 2 , R 4 , X, m, n and p are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物 其中 R 1 ，R 2 ，R 4 ，X，m，n和p的定义如权利要求书中所述 ，适用于治疗以细胞过度或异常增殖为特征的疾病，并且用于制备具有上述特性的药物组合物。
• Antimicrobial N-acyl-2-azetidinones
  申请人：THE UPJOHN COMPANY

  公开号：EP0232017A1

  公开（公告）日：1987-08-12

  The present invention provides novel compositions of matter and processes for their preparation. Particularly, the present invention relates to novel monocyclic β-lactams of formula I, having a carbonyl group, other than a negatively charged group, attached to the N-1 position. The compounds are useful as antimicrobial agents or as intermediates thereto. The present invention also provides a novel process for making these compounds which utilizes palladium (O)-­catalyzed carbonylation of an appropriate 2-bromo-1-propen-3-yl amine and novel intermediates prepared by this process.

  本发明提供了一种新的物质组合物及其制备过程。特别是，本发明涉及一类新型的单环β-内酰胺类化合物，其具有一个羰基团，而不是一个负电荷团，连接到N-1位置。这些化合物可用作抗菌剂或作为其前体。本发明还提供了一种制造这些化合物的新过程，该过程使用钯(0)催化的2-溴-1-丙烯-3-基胺的羰基化反应，以及通过该过程制备的新型中间体。
• Efficient synthesis of (1R,2S) and (1S,2R)-2-aminocyclopentanecarboxylic acid ethyl ester derivatives in enantiomerically pure form
  作者：Peter S. Dragovich、Douglas E. Murphy、Kimkim Dao、Sun Hee Kim、Lian-Sheng Li、Frank Ruebsam、Zhongxiang Sun、Chinh V. Tran、Alan X. Xiang、Yuefen Zhou

  DOI：10.1016/j.tetasy.2008.11.029

  日期：2008.12

  applications. In addition, the straightforward conversion of compound 12 to enantiomerically pure (1R,2S)-2-aminocyclopentanecarboxylic acid ethyl ester and the corresponding Boc and Cbz derivatives is reported. The preparation of the enantiomer of 12 (compound 15) in enantiomerically pure form and the conversion of this entity to (1S,2R)-2-aminocyclopentanecarboxylic acid ethyl ester and the corresponding

  旋光合成中间体[（1 R，2 S）-2-（4'-氟苄氨基）环戊烷羧酸乙酯与（S）-（+）-扁桃酸的络合物的四步合成；据报道制备有希望的HCV NS5B聚合酶抑制剂所需的化合物12，＞ 99％de]。该方法利用扁桃酸作为拆分剂，可通过简单的提取以高收率回收。所描述化学方法的优化版本避免了使用色谱纯化方法，使其适合大规模应用。此外，化合物12直接转化为对映体纯的（1 R，2 S报道了）-2-氨基环戊烷羧酸乙酯和相应的Boc和Cbz衍生物。的对映体的制备12（化合物15）的对映体纯的形式和该实体的（1转换小号，2 - [R）-2-氨基环戊烷羧酸乙酯和相应的Boc和Cbz基衍生物也被描述。